Eli Lilly (NY:LLY)

1,146.15 +3.30 (+0.29%)

Delayed Quote Updated: 11:24 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

99 100 Next >

The AI Engine: S&P 500 Defies Gravity with 13.3% Q4 Growth as Tech Titans Carry the Weight

April 07, 2026

The fourth-quarter 2025 earnings season has officially drawn to a close, leaving market analysts and investors in awe of the S&P 500’s resilience. Defying high interest rates and a cooling labor...

Via MarketMinute

Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval

April 07, 2026

The number of oral weight-loss / diabetes drug treatments is expanding, increasing demand for the reduction of side effects

Via TheNewswire.com

Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’

April 06, 2026

On March 31, 2026, Eli Lilly and Company (NYSE:LLY) sent shockwaves through the biotechnology sector by announcing a definitive agreement to acquire Centessa Pharmaceuticals (Nasdaq:CNTA) for a total...

Via MarketMinute

Lilly’s $47.8 Billion Bet: Why the Contessa Acquisition Redefines the Future of Medicine

April 06, 2026

In a move that has sent shockwaves through both the pharmaceutical and technology sectors, Eli Lilly and Company (NYSE: LLY) announced today, April 6, 2026, the finalized acquisition of Contessa, a...

Via MarketMinute

Topics Artificial Intelligence

Productivity Surge and Falling Jobless Claims: The New U.S. Labor Paradigm

April 06, 2026

The United States labor market is currently defying traditional economic gravity, showcasing a resilient "low-hire, low-fire" dynamic that has left analysts and investors recalibrating their...

Via MarketMinute

Topics Artificial Intelligence Economy Energy

S&P 500 Snaps Five-Week Slump with 3.4% Tech-Led Surge Amid Middle East De-escalation Hopes

April 06, 2026

The S&P 500 (NYSEARCA:SPY) concluded the week ending April 4, 2026, with a resounding 3.4% rally, marking its strongest weekly performance since late 2025. This surge effectively halted a grueling...

Via MarketMinute

Topics Artificial Intelligence Bonds ETFs

Goldman Sachs Forecasts 12% S&P 500 Surge in 2026: The Five Pillars of a Maturing Bull Market

April 06, 2026

As the second quarter of 2026 kicks off, the investment landscape is being defined by a renewed sense of optimism from Wall Street’s most influential voices. Goldman Sachs (NYSE: GS) has officially...

Via MarketMinute

Topics Artificial Intelligence Economy Initial Public Offering

The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports

April 06, 2026

In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded...

Via MarketMinute

Topics Economy World Trade

Nuclear, Pharma & Travel Buybacks: Confident or Cautious Signals? ↗

April 06, 2026

Via MarketBeat

2 Cash-Producing Stocks with Impressive Fundamentals and 1 We Brush Off

April 06, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...

Via StockStory

3 of Wall Street’s Favorite Stocks with Questionable Fundamentals

April 06, 2026

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...

Via StockStory

Topics Artificial Intelligence

Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight ↗

April 04, 2026

The U.S. Food & Drug Administration just approved Eli Lilly's GLP-1 pill orforglipron.

Via The Motley Fool

The Next Big AI Winner Might Not Be a Tech Company

April 04, 2026

Lilly’s AI push shows how non-tech firms can dominate the next wave.

Via Barchart.com

Topics Artificial Intelligence

The Second-Best Performing Vanguard ETF Over the Last Decade Is Issuing a 5-For-1 Stock Split. Here's Why It's a Screaming Buy in April. ↗

April 04, 2026

The Vanguard Mega Cap Growth ETF is down big from its highs as the largest tech stocks lead the broader market sell-off.

Via The Motley Fool

Topics ETFs

Earnings Revision Momentum: Why Analysts Upgraded S&P 500 Growth to 17%

April 03, 2026

As of April 3, 2026, the financial landscape is witnessing a historic disconnect between gritty macroeconomic headlines and exuberant corporate fundamentals. Despite a backdrop of stubborn...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Why Novo Nordisk's Pricing Shift Could Unlock a Much Larger Obesity Market ↗

April 03, 2026

The drugmaker hasn't said its last word yet, as the weight-loss drug battle continues to heat up.

Via The Motley Fool

Where Will Viking Therapeutics Stock Be in 10 Years? ↗

April 03, 2026

There is a wide range of possibilities.

Via The Motley Fool

The Great Metabolic Land Grab: Why Viking and Structure Have Become Big Pharma’s 'Irresistible' Targets

April 03, 2026

As of April 2026, the biotech landscape has undergone a seismic shift, moving from the "hype cycle" of early weight-loss treatments into an era of aggressive strategic consolidation. The market for...

Via MarketMinute

Topics Intellectual Property

Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptcy ↗

April 03, 2026

Major M&A deals this week include: Eli Lilly's $7.8 billion purchase of Centessa Pharmaceuticals; Meanwhile, IO Biotech goes bankrupt.

Via Benzinga

Trump Issues Landmark Executive Order: 100% Tariffs on Imported Patented Drugs to Force Onshoring

April 03, 2026

WASHINGTON, D.C. — In a move that has sent shockwaves through the global healthcare industry, President Trump signed a sweeping executive order yesterday, April 2, 2026, imposing a baseline 100% tariff...

Via MarketMinute

Topics Economy Government Lawsuit

Regeneron Pharmaceuticals: The Scientific Juggernaut Navigating a High-Stakes Transformation

April 03, 2026

By Financial Research Feature April 3, 2026 Introduction In the high-stakes arena of global biotechnology, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has long stood as a paragon of scientific...

Via Finterra

Topics Economy Intellectual Property World Trade

2 No-Brainer Vanguard ETFs to Buy During the Stock Market Sell-Off ↗

April 03, 2026

Throughout history, investors who bought during stock market declines while maintaining a long-term outlook yielded strong returns.

Via The Motley Fool

Topics ETFs Economy

Dow, S&P 500, Nasdaq: From Morning Meltdown to Midday "Meh" ↗

April 02, 2026

Markets opened lower on Iran fears and a Tesla stumble, but bounced back. Here's what investors need to know about Thursday's volatile session.

Via The Motley Fool

Topics Government Stocks World Trade

Eli Lilly Secures Landmark FDA Approval for Oral Weight-Loss Pill, Sending Shares Soaring

April 02, 2026

Shares of Eli Lilly and Company (NYSE: LLY) surged 3.8% on Wednesday following the milestone FDA approval of Foundayo (orforglipron), the first once-daily oral weight-loss pill that does not require...

Via MarketMinute

Topics Economy

Stock Market Rebounds Even As Oil Prices Skyrocket On Trump's Iran War Comments; Tesla, SpaceX, Eli Lilly In Focus: Weekly Review ↗

April 02, 2026

Tesla deliveries disappointed while Elon Musk's SpaceX filed for an IPO.

Via Investor's Business Daily

Topics Government

Lilly's Next Empire: A $10 Billion Bet on AI and Neuroscience ↗

April 02, 2026

In a powerful demonstration of financial strength and strategic foresight, Eli Lilly and Company (NYSE: LLY) recently committed over $10 billion to two major initiatives in just a matter of days. While...

Via MarketBeat

Topics Artificial Intelligence

How Novo Nordisk Is Striking Back As Eli Lilly Plans Its Newest Weight-Loss Launch ↗

April 02, 2026

Novo Nordisk said Thursday a new study suggests patients prefer its oral Wegovy over Eli Lilly's new GLP-1 pill, Foundayo.

Via Investor's Business Daily

The Evolution of The Cigna Group: A Deep Dive into a Health Services Powerhouse (2026)

April 02, 2026

April 2, 2026 Introduction The Cigna Group (NYSE: CI) stands today at a pivotal crossroads, having undergone one of the most significant strategic transformations in the modern healthcare era. Long...

Via Finterra

Topics Artificial Intelligence Economy Lawsuit

The Trillion-Dollar Treatment: A Deep Dive into Eli Lilly and Company (LLY)

April 02, 2026

As of April 2, 2026, Eli Lilly and Company (NYSE:LLY) stands as the preeminent titan of the global healthcare sector. Historically recognized as a steady, century-old pharmaceutical giant, the company...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

Eli Lilly Stock Slips Despite Foundayo Approval As Geopolitical Tensions Weigh ↗

April 02, 2026

Eli Lilly & Co shares are down Thursday despite FDA approval of its oral weight-loss drug Foundayo, as geopolitical tensions weigh on markets.

Via Benzinga

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.